Ivanov Stefan, Bozinovski Steven, Bossios Apostolos, Valadi Hadi, Vlahos Ross, Malmhäll Carina, Sjöstrand Margareta, Kolls Jay K, Anderson Gary P, Lindén Anders
Lung Pharmacology & Immunology Groups, Department of Internal Medicine/Respiratory Medicine and Allergology, Institute of Medicine, Sahlgrenska Academy at Göteborg University, Guldhedsgatan 10A, S-413 46 Gothenburg, Sweden.
Am J Respir Cell Mol Biol. 2007 Apr;36(4):442-51. doi: 10.1165/rcmb.2006-0020OC. Epub 2006 Dec 1.
It is known that interleukin (IL)-23, an IL-12-family cytokine, can be released by certain antigen-presenting cells in response to bacterial pathogens. Recent in vitro studies indicate that this cytokine stimulates a unique subset of CD4 cells, the T helper cell (Th)17 subset, to produce and release the proinflammatory cytokine IL-17. However, it has not been known whether this is an action of IL-23 per se that has bearing for the early innate response in lungs in vivo and whether there is an IL-23-responsive population of IL-17-producing CD4 cells in the bronchoalveolar space. We now present evidence that IL-23 can be involved in the early innate response to both gram-negative and gram-positive bacterial products in the lungs: Recombinant IL-23 protein per se accumulates inflammatory cells in the bronchoalveolar space in part via endogenous production of IL-17, and this IL-17 production occurs locally in IL-23-responsive CD4 cells. This IL-17 response to IL-23 occurs without any pronounced impact on Th1/Th2 polarization. Moreover, recombinant IL-23 protein increases the local MMP-9 activity, which is generated by neutrophils mainly. CD4 cells in the lungs may thus respond to IL-23 from antigen-presenting cells exposed to gram-negative and gram-positive pathogens and thereby reinforce the early innate response. These findings support that IL-23 and IL-17 form a functionally relevant "immunological axis" in the lungs in vivo.
已知白细胞介素(IL)-23是一种IL-12家族细胞因子,可由某些抗原呈递细胞响应细菌病原体而释放。最近的体外研究表明,这种细胞因子刺激CD4细胞的一个独特亚群,即辅助性T细胞(Th)17亚群,产生并释放促炎细胞因子IL-17。然而,尚不清楚这是否是IL-23本身的作用,对体内肺部早期固有反应有影响,以及在支气管肺泡间隙中是否存在对IL-23有反应的产生IL-17的CD4细胞群体。我们现在提供证据表明,IL-23可参与肺部对革兰氏阴性和革兰氏阳性细菌产物的早期固有反应:重组IL-23蛋白本身部分通过内源性IL-17的产生在支气管肺泡间隙中聚集炎症细胞,并且这种IL-17的产生发生在对IL-23有反应的CD4细胞局部。这种对IL-23的IL-17反应对Th1/Th2极化没有任何明显影响。此外,重组IL-23蛋白增加局部MMP-9活性,这主要由中性粒细胞产生。肺部的CD4细胞因此可能对来自暴露于革兰氏阴性和革兰氏阳性病原体的抗原呈递细胞的IL-23作出反应,从而加强早期固有反应。这些发现支持IL-23和IL-17在体内肺部形成功能相关的“免疫轴”。